Mark Nichols

Background

About Mark Nichols

PhD- Yale University- Molecular Biophysics & BiochemistryBA- University of California, Berkeley- BiochemistryResearch at EMBL in Heidelberg, Germany after post-doc in German Cancer Research CenterMolecular Biology expertise (photo day before running marathon Oct 2025)•UMKC Interim Vice Chancellor for Research & Economic Development (Jan-Aug 2019), fostered collaborative research to grow federal research funding and clinical translational research. Now Chair, Director for Research Development School of Medicine (SOM), mentor faculty, review science and grant applications to federal agencies NIH, NSF, DoD, HRSA. In the past decade, revised the science/grantsmanship of 96 funded NIH+ applications for >$192 million; many PIs received 1st-time funding or 1st renewals. UMKC SOM has grown funding by 1200% since arrival in 2016, UMKC is now Carnegie R1•Med school tenured faculty, department chair, course director, consultant, expert witness, biomedical researcher in molecular biology, pharmacology, oncology, endocrinology for 25 years with focus on estrogens, breast cancer, tamoxifen regulated Cre/Flp, steroids, protein receptors, gene expression, oncology precision medicine. Medical education lectures, seminars for MD, PA, PhDs•Expert on molecular mechanisms of drug and enzyme action, mutagenesis, cloning, signal transduction, genome regulation, pharmaceutical drug mechanisms, therapeutic development, healthcare; mitochondria, TCA Krebs cycle, ETC, bioenergetics, and anti-aging; peer-reviewed publications in 20 biomedical journals; inventor on biotechnology siRNA patent•Consulting for law firms- biomedical topics- scientific review, search, discovery. Work-product led to win in a lung cancer case; Consultant on estrogen/progestin HRT in breast cancer patients (2 cases); Expert witness in patent case/generic drug application to FDA with excellent settlement; Consultant on contraceptive hormone risks•PublicationsSingh et al (2025 Apr) Bioinformatics and AI/ML approaches using multiomics data to accelerate diagnosis and delivery of precision care for patients with rare diseases. Meth in Cell Biology. doi.org/10.1016/bs.mcb.2025.03.018Genome-Wide Transcript Profiling Reveals Novel Breast Cancer-Associated Intronic Sense RNAs. PLOS ONE 10(3):e0120296, 2015M Nichols, New directions for drug-resistant breast cancer: the CDK4/6 inhibitors. Future Med Chem. 2015, 7:1473-81Nichols et al. Breast cancer-derived M543V mutation in helix 12 of estrogen receptor alpha inverts response to estrogen and SERMs. Breast cancer research & treatment.